Aligos Therapeutics saw the highest growth of 0.99% in patent filings and 2.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 2.99%. GlobalData’s DataBook provides a comprehensive analysis of Aligos Therapeutics‘s patent filings and grants. Buy the databook here.
Aligos Therapeutics has been focused on protecting inventions in United States(US) with eight publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 24% filings and 100% grants. The World Intellectual Property Organization(WIPO), United States(US), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Aligos Therapeutics is filings its patents. Among the top granted patent authorities, Aligos Therapeutics has 100% of its grants in United States(US).
Gilead Sciences and Roche could be the strongest competitors for Aligos Therapeutics
Patents related to Covid-19 and rare diseases lead Aligos Therapeutics's portfolio
Aligos Therapeutics has the highest number of patents in Covid-19 followed by, rare diseases. For Covid-19, nearly 57% of patents were filed and 25% of patents were granted in Q2 2024.
Hepatitis b related patents lead Aligos Therapeutics portfolio followed by coronaviridae infections, and coronavirus disease 2019 (covid-19)
Aligos Therapeutics has highest number of patents in hepatitis b followed by coronaviridae infections, coronavirus disease 2019 (covid-19), hepatitis d, and human immunodeficiency virus (hiv) infections (aids). For hepatitis b, nearly 17% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Aligos Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.